Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Notable: XH-S003 Capsules · Paroxysmal Nocturnal Hemoglobinuria (PNH) Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Notable: Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation Phase changed: Phase 2/3 → Phase 3
- Notable: IMPACT-MACS · Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Phase changed: Not applicable → Phase 4
- Notable: Multimodal AI-based Region-specific Ablation Planning for Hepatocellular Carcinoma: Model Development, External Validation, and a Multicenter Randomized Trial Phase changed: Not specified → Not applicable
- Notable: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Recruitment opened
- Notable: Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules · Early-Onset Parkinson's Disease Recruitment opened
- Notable: SYNCHRONIZE®-HERA · Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Recruitment opened
- Notable: GC3114B in Adults Aged 65 Years or Older Recruitment opened
- Notable: IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis · Chronic Hepatitis B Recruitment opened
- Notable: ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs Recruitment opened
- Notable: Continuation Study of Tilrekimig · Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time Recruitment opened
- Notable: Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors Recruitment opened
- Notable: RT023 · Advanced Solid Tumors Recruitment opened
- Notable: MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Recruitment opened
- Notable: GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) Recruitment opened
- Notable: Modzatinib (ATI-2138) · Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies Recruitment opened
- Notable: BMS-986511 · Major Depressive Disorder Recruitment opened
- Notable: SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer Recruitment opened
- Notable: LY4247147 · Obesity or Overweight Who Are Otherwise Healthy Recruitment opened
- Notable: HH-1270 in Healthy Chinese Subjects Recruitment opened
- Notable: LY4560736 in Healthy Participants and · Alzheimer's Disease (AD) Recruitment opened
- Notable: LY4167586 · Obesity or Overweight With or Without Type 2 Diabetes Recruitment opened
- Notable: LY4515100 in Healthy Male Participants Recruitment opened
- Notable: LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and · Inflammation (High C-Reactive Protein) Recruitment opened
- Notable: Dietary Supplement to Alleviate Dry Mouth Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates